Thrombopoietin Receptor
MPLproteinMPL signaling modulates platelet mass and functional state, influencing thrombotic response at coronary lesion.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleRegulates platelet production and activation in coronary thrombosis.
Druggability
DruggableYes
Known drugs / candidates9
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000117400
Type I vs Type II discrimination
ScoresShared / rises in both
R — rupture / Type-I67
C — confounder / Type-II67
A — assay feasibility72
E — evidence strength59
T1DI (composite)21
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 1/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 3 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Alterations in platelet proteome signature and impaired platelet integrin αβactivation in patients with COVID-19.Journal of thrombosis and haemostasis : JTH · 2023 · PMID 36716966 · doi